Abstract
The development of second generation ultrasound contrast agents has extended the diagnostic scope of ultrasound imaging. Due to their physical characteristics, a therapeutic application of such microbubble based contrast agents has been promoted. Recently, several groups have demonstrated that ultrasound targeted microbubble destruction (UTMD) may deliver drugs or gene therapy vectors to organs accessible by ultrasound, thus providing a new technique for non-invasive, organ specific delivery of bioactive substances. Most applications in this field have been tested in cardiac models, but other organs can be treated as well. This article will give an overview of the background of UTMD and its non-cardiac applications.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Ultraschall in der Medizin - European Journal of Ultrasound
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
